Answers are grounded in this paper and cite their sources.
Diabetic kidney disease (DKD) stands as a paramount microvascular complication of diabetes, now recognized globally as the primary driver of end-stage renal disease. Recent years have witnessed intensive scrutiny into how gut microbiota, operating through the “gut–kidney axis,” orchestrate the onset and advancement of DKD. Patients with DKD manifest a bidirectional dysbiosis: a depletion of beneficial short-chain fatty acid (SCFA)-producing bacteria coincides with an enrichment of pathogenic or opportunistic strains. This microbial imbalance precipitates a dual crisis—insufficient production of protective metabolites like butyrate alongside the accumulation of gut-derived uremic toxins such as indoxyl sulfate (IS), p-cresyl sulfate (pCS), and trimethylamine N-oxide (TMAO). Acting in concert, these metabolites fuel renal inflammation, oxidative stress, and fibrosis by activating diverse signaling cascades, including TLR4/NF-κB and NLRP3 inflammasome. Emerging intervention strategies aimed at modulating the gut microbiota—ranging from dietary adjustments and probiotics/prebiotics to fecal microbiota transplantation and natural products—have demonstrated promise in retarding DKD progression. This review synthesizes current insights into the mechanisms and research trajectories linking gut microbiota and their metabolites to DKD, striving to establish a robust theoretical foundation for clinical translation.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: